ImmunityBio (IBRX) Resubmits sBLA to FDA for ANKTIVA in Papillary Bladder Cancer

ImmunityBio Inc. (NASDAQ:IBRX) is one of the most buzzing stocks to buy with the highest upside potential. On March 9, ...

NCCN Guideline Expansion Puts ANKTIVA And ImmunityBio Growth In Focus

NCCN has added ImmunityBio's ANKTIVA to its Clinical Practice Guidelines for BCG-unresponsive non muscle invasive bladder cancer with papillary only disease. This update extends recognized use of ...
Nature

Reduction of mitral valve regurgitation caused by acute papillary muscle ischemia

Background A 67-year-old man was admitted to a coronary care unit for non-ST-segment elevation myocardial infarction with complicating acute heart failure. Severe mitral regurgitation was detected by ...
The American Journal of Managed Care

Papillary Muscle Scarring May Predict Cardiac Death in Dilated Cardiomyopathy

Papillary muscle scarring (papSCAR) is prevalent in one-third of DCM patients and predicts cardiac death independently. The FIDDLE technique significantly improves papSCAR detection sensitivity ...
Targeted Oncology

NCCN Adds Nogapendekin to Bladder Cancer Guidelines

The combination of nogapendekin alfa inbakicept-pmln (Anktiva) and Bacillus Calmette-Guérin was added to the NCCN clinical ...
CURE

NCCN Guidelines Expand Options for Certain Bladder Cancer Patients

NCCN now includes Anktiva plus BCG for BCG-unresponsive papillary-only NMIBC, acknowledging an unmet need in patients without CIS who have limited post-BCG options. Radical cystectomy remains ...
PharmiWeb

ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA® Plus BCG for Patients With BCG-Unresponsive NMIBC With Papillary ...

Recommendation is based on peer-reviewed clinical data supporting long-term effectiveness and safety durability in patients with papillary-only disease treated with ANKTIVA plus BCG1.CULVER CITY, ...